Tilos has a rich pipeline of anti-LAP antibodies with attributes suited to a broad range of distinct clinical indications. The over-riding philosophy is that by targeting the primary pathological process for a particular indication, one can significantly improve the therapeutic outcome for patients. The following examples serve to illustrate the power and value of this diverse portfolio.

  • The extracellular matrix is believed to store the majority of latent TGFβ in the body. Tilos has anti-LAP antibodies that in addition to depleting immuno-suppressive cells, can inhibit TGFβ release from inhibitory cells while leaving LAP-TGFβ in the ECM untouched. This is anticipated to specifically inhibit pathological and immuno-regulatory processes, while avoiding interfering with the normal tissue homeostasis processes mediated by TGFβ.

  • The depot of latent TGFβ in the extracellular matrix is thought to be critical in driving fibrotic processes associated with cancers. Tilos has anti-LAP antibodies that can inhibit TGFβ release from the ECM, which may be most effective in the treatment of desmoplastic tumors.

  • Different cancers have distinct tumor microenvironments dominated by different cellular infiltrates. Tilos has anti-LAP antibodies that can preferentially bind to LAP+ MDSC relative to LAP+ Treg, leading to preferential depletion of this inhibitory cell population. These antibodies are expected to have increased anti-tumor activity in MDSC-dominated tumors, with an additional benefit of a more favorable side effect profile.

  • TGFβ release drives the development of Tregs. Tilos has antibodies that destabilize the LAP-TGFβ complex and enhance release of the mature cytokine, which we believe will drive local induction of Tregs and be useful for the treatment of autoimmune disease.